Featured Research

from universities, journals, and other organizations

A New Paradigm For Anti-Angiogenesis Therapy

Date:
September 14, 2001
Source:
Massachusetts General Hospital
Summary:
The aim of anti-angiogenesis therapy is to target the abnormal blood vessels growing into a tumor and cut off the blood supply to a cancerous mass. Yet, without an effective blood flow into a tumor, other treatments such as chemotherapy and even radiation cannot effectively reach their targets.

The aim of anti-angiogenesis therapy is to target the abnormal blood vessels growing into a tumor and cut off the blood supply to a cancerous mass. Yet, without an effective blood flow into a tumor, other treatments such as chemotherapy and even radiation cannot effectively reach their targets.

Rakesh Jain, PhD, of the Massachusetts General Hospital (MGH) Department of Radiation Oncology is now suggesting another, somewhat paradoxical strategy for anti-angiogenic treatment. He outlines the approach in a commentary published in this month's issue of Nature Medicine. "If we normalize the tumor vasculature before its destruction, we can actually improve the efficiency of current cancer therapies, Jain says.

Jain's insight stems from his laboratory observations over the years. His team of researchers saw that the tumor vasculature is made up of very disorganized and abnormal blood vessels, which make it difficult for blood to flow smoothly and completely into a tumor.

This creates an obstacle for cancer treatments: radiation therapy depends on oxygen delivered from the blood, and chemotherapy depends on drugs delivered by good blood flow. "If we prune the tumor's blood vessels and remodel them to become more normal, we can improve the delivery of drugs and other treatments," says Jain.

Interestingly, Jain's group has found that anti-angiogenic agents seem to be good at this sort of pruning, a fact that researchers previously hadn't realized. "We've found that a number of therapeutics actually improve the efficiency of blood vessels before they destroy them," says Jain.

Jain says the key is to find the appropriate dose and schedule of anti-angiogenic drugs that can complement other treatments. "Taking advantage of this new concept is important in order to get the most out of chemotherapy and radiation," says Jain. Clinical trials based on Jain's paradigm are planned at MGH.

He believes his strategy will optimize conditions so that doctors will be able to administer lower doses of cancer-fighting treatments, thereby sparing patients many of the harmful side effects of these agents.

The Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $300 million and major research centers in AIDS, the neurosciences, cardiovascular research, cancer, cutaneous biology, transplantation biology and photomedicine. In 1994, the MGH joined with Brigham and Women?s Hospital to form Partners HealthCare System, an integrated health care delivery system comprising the two academic medical centers, specialty and community hospitals, a network of physician groups and nonacute and home health services.


Story Source:

The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.


Cite This Page:

Massachusetts General Hospital. "A New Paradigm For Anti-Angiogenesis Therapy." ScienceDaily. ScienceDaily, 14 September 2001. <www.sciencedaily.com/releases/2001/09/010914073755.htm>.
Massachusetts General Hospital. (2001, September 14). A New Paradigm For Anti-Angiogenesis Therapy. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2001/09/010914073755.htm
Massachusetts General Hospital. "A New Paradigm For Anti-Angiogenesis Therapy." ScienceDaily. www.sciencedaily.com/releases/2001/09/010914073755.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins